RxDoctor Payments Data

Amanda Fondren

Family · Columbus, MSNPI 1851792626

Payments from drug & device makers

$383in general payments, 2019–2025

Across 20 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$227
  • Xeris Pharmaceuticals, Inc.$43
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$42
  • Lilly USA, LLC$21
  • Acella Pharmaceuticals, LLC$18
  • Novo Nordisk$18
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$383 in reported general payments places this provider in the 50th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$75,535
Medicare patients
188
Services billed
2,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$56,690
MounjaroTirzepatide31$41,921
Invega SustennaPaliperidone Palmitate13$30,223
TrulicityDulaglutide21$20,991
JardianceEmpagliflozin13$16,025
FarxigaDapagliflozin Propanediol11$9,542
Liothyronine Sodium49$1,409
Gabapentin84$1,155
Metformin Hcl ErMetformin Hcl99$1,009
Np ThyroidThyroid,pork25$872
Duloxetine Hcl32$847
Levothyroxine Sodium114$845
Fluoxetine Hcl13$759
Armour ThyroidThyroid,pork20$700
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$21$62,91252 claims
Novo NordiskOzempic$18$56,69052 claims
Acella Pharmaceuticals, LLCNp Thyroid$18$87225 claims
AbbVieArmour Thyroid$227$70020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,007 family providers in Mississippi.

Other family in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →